Pediatric Lipid Guidelines
Criteria for Lipid screening
- Age 0-12 months: No routine lipid screening is recommended
- Age 2-8 years: Measure fasting lipid profile only in high risk population
- Positive Family history of premature cardiovascular disease
- Parent with total cholesterol TC > 240 mg/dL or known dyslipidemia
- If the parent had diabetes, hypertension, BMI>95 th percentil and/or smokes cigarettes
- Age 9-11 years: Measure non-fasting lipid profile in all patients to look at non-HDL
- Non-HDL=Total Cholesterol - HDL
- Age 12-17 years: Measure fasting lipid profile in high risk populations (as above + BMI > 85th percentile)
- Age 18-21 years: Measure non-fasting lipid profile in all patients to look at non-HDL
Definition of Abnormal Results and Recommendations for Initial Primary Care Management and Follow-up or Referral to COA Lipid Clinic
* please note that isolated total cholesterol may not represent cardiovascular risk, especially if HDL is >45 mg/dL. Therefore, our focus is LDL, non-HDL, and triglycerides.
LDL/non-HDL
| Results | Intervention |
|---|---|
| LDL < 160mg/dL and/or Non-HDL < 160. Non-HDL=TC-HDL |
|
| LDL>160 mg/dL and/or Non-HDL>160 mg/dL | All of the above plus initiate referral to Lipid Clinic |
Triglycerides
| Results | Intervention |
|---|---|
| Fasting Triglycerides < 300 mg/dL |
If non-fasting level is elevated, first repeat fasting lipid panel
|
| Triglycerides>300 mg/dL |
|
Lifestyle intervention should be taught for overweight patients
- Consider consult with registered dietician or nutritionist
- Increase activity level to a goal of 60 minutes/day; decrease sedentary time with TV/computer games; take TV out of the bedroom
- Limit portion sizes, fried and fatty food diet
- Elimiate All sweet drinks from diet (juices, sodas, Gatorade, Kool-Aid, sweet tea, etc) and choose sugar-free alternatives or water. Consider switching to 1% milk (or fat free) and limiitng consumption
Consider Metformin in patient over 10 years old who have markedly increased diabetes risk (morbid obesity, strong family history of diabetes, etc) or poor response to lifestyle interventions.
- Adjust treatment with Metformin may be added to hlep decrease insulin resistance and potentially prevent/delay progression to over diabetes and cardiovascular morbidity. Regrettably, to date, evidence-based long-term studies regarding the efficacy of Metformin in pediatric prediabetes is lacking.
- Starting dose - 500 mg PO BID. Can be titrated to 1000mg PO BID in older children.
- Low starting dose (i.e. 250 mg PO BID, slowly titrated to final dose over 1-2 weeks) can decrease GI upset associated with initiation of therapy, but are not necessary.